2-Methoxy-5-[3-(4-methylphenyl)-5-sulfanylidenedithiol-4-yl]benzenesulfonic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methoxy-5-[3-(4-methylphenyl)-5-sulfanylidenedithiol-4-yl]benzenesulfonic acid
• 化学式: C₁₇H₁₄O₄S₄
• 分子量: 410.6
• InChiKey: YNPXWCRALUSFSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  155
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• 1,2-Dithiole derivatives and therapeutic agents containing them
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0641792A1

  公开（公告）日：1995-03-08

  Novel 1,2-dithiole-3-thione derivatives represented by general formulas (1) and (11); processes for production thereof; and therapeutic or preventive agents for diseases associated with peroxylipid, each containing said derivative as the active ingredient.

  由一般式（1）和（11）代表的新型1,2-二硫代-3-硫酮衍生物；其生产方法；以及作为活性成分含有该衍生物的与过氧脂类相关疾病的治疗或预防剂。
• Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
  申请人：Patrick Prendergast

  公开号：US20040053989A1

  公开（公告）日：2004-03-18

  The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to patients, or delivering to the tissues of such patients, oltipraz or related compounds as disclosed in the specification.

  该发明提供了治疗神经系统疾病，如阿尔茨海默病的方法，或减缓这些疾病的进展，或治疗和/或预防其他疾病的方法，通过向患者或向这些患者的组织输送在规范中披露的oltipraz或相关化合物。
• [EN] DITHIOLTHIONE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND FOR MEMORY ENHANCEMENT<br/>[FR] COMPOSES DITHIOLTHIONE POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET POUR RENFORCER LA MEMOIRE
  申请人：PRENDERGAST PATRICK T

  公开号：WO2001009118A2

  公开（公告）日：2001-02-08

  The invention provides methods to treat neurological disorders such as Alzheimer's disease, or to slow the progression of such diseases, or to treat and/or prevent other disorders as disclosed in the specification, by administering to patients, or delivering to the tissues of such patients, oltipraz or related compounds as disclosed in the specification.